Cerdulatinib HCl salt manufacturers
|
| Cerdulatinib HCl salt Basic information |
Product Name: | Cerdulatinib HCl salt | Synonyms: | Cerdulatinib HCl salt;4-(cyclopropylamino)-2-[[4-[4-(ethylsulfonyl)-1-piperazinyl]phenyl]amino]-5-pyrimidinecarboxamide,hydrochloride (1:1);Cerdulatinib (PRT062070, PRT2070);Cerdulatinib HCl;Cerdulatinib hydrochloride;Cerdulatinib HCl salt USP/EP/BP;PRT2070 hydrochloride;PRT062070 hydrochloride | CAS: | 1369761-01-2 | MF: | C20H28ClN7O3S | MW: | 481.99942 | EINECS: | | Product Categories: | Inhibitors | Mol File: | 1369761-01-2.mol | |
| Cerdulatinib HCl salt Chemical Properties |
storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | solubility | DMSO:20.0(Max Conc. mg/mL);41.49(Max Conc. mM) | form | Solid | color | Light brown to brown |
| Cerdulatinib HCl salt Usage And Synthesis |
Biological Activity | Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an orally active multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 for JAK1/JAK2/JAK3/TYK2 and Syk, respectively nM and 32 nM. Also inhibits 19 other kinases tested with IC50s below 200 nM. | in vitro | Cerdulatinib affects BCR-mediated B cell activation through dual inhibition of SYK and JAK in human whole blood from normal donors. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduced cell viability in a subset of NHL cell lines and induced apoptosis in NHL cell lines with BCR signaling. | in vivo | In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg po) significantly improved inflammatory infiltration of synovium and articular cartilage integrity. In addition, cerdulatinib also blocked BCR-induced B cell activation and splenomegaly in mice. | target | Target | Value | TYK2 (Cell-free assay) | 0.5 nM | MST1 (Cell-free assay) | 4 nM | < td style="border-bottom: 1px dotted #ccc;padding: 5px;"> ARK5 (Cell-free assay) 4 nM | MLK1 (Cell-free assay) td> | 5 nM | Fms (Cell-free assay) | 5 nM |
|
| Cerdulatinib HCl salt Preparation Products And Raw materials |
|